Varian Medical Systems Investor Presentation — October 2018

Document content

FOR INVESTOR USE ONLY

Welcome & Introductions

SVP, Investor Relations, Corporate Planning & Segment Finance

Varian Overview & Strategic Framework

Dow WilsonPresident and Chief Executive Officer

Innovations in Oncology

Kolleen KennedyChief Growth Officer and President , Proton Solutions

Chris TothPresident, Oncology Systems

SVP, Oncology Software Solutions

New Horizons in Cancer Care

Dee Khuntia, MDChief Medical Officer

Dow WilsonPresident and Chief Executive Officer

Questions & AnswersThis presentation is intended exclusively for investors.

It is not intended for use in Sales or Marketing.

Forward- Looking Statements

Except forhistorical information, thispresentation contains forward -looking statements within themeaning ofthePrivate Securities Litigation Reform Actof1995 .Statements

concerning industry outlook, including growth drivers, future trends incancer incidence andtrends incancer treatment needs, demand, innovation andgrowth opportunities ;Varian

Medical System, Inc.’s(”Varian” orthe“company”) future orders, revenues, backlog orearnings growth ;future financial results ;market acceptance ofortransition tonew products or

technology such asourEdge®radiosurgery system, TrueBeam®,HyperArcTM,360OncologyTM,HALCYONTM,image -guided radiation therapy, stereotactic radiosurgery andproton

therapy, and any statements using theterms “could”, “believe”, “expect”, “outlook”, “anticipate”, ”vision”, “estimate”, “future”, “horizon”, “aiming”, “driving”, “target” orsimilar

statements areforward -looking statements thatinvolve risks anduncertainties thatcould cause thecompany’s actual results todiffer materially from those anticipated .Such risks

anduncertainties include global economic conditions andchanges totrends forcancer treatment regionally ;new andpotential future tariffs oraglobal trade war;theimpact of

changes totheAffordable Health Care forAmerica Act(including excise taxes onmedical devices) and anyfurther healthcare reforms (including changes toMedicare and

Medicaid), and/or changes tothird-party reimbursement levels ;currency exchange rates andtaxrates ;theimpact oftheTaxCuts andJobs Act;demand forthecompany’s products ;

thecompany’s ability todevelop, commercialize, anddeploy new products ;thecompany’s ability tomeet Food andDrug Administration (FDA) andother regulatory requirements for

product clearances ortocomply with FDA andother regulatory regulations orprocedures, changes intheregulatory environment, including with respect toFDA requirements ;the

company’s assessment ofthegoodwill associated withitsproton business, challenges associated withthesuccessful commercialization ofthecompany’s proton business ;therisks